Olema Pharmaceuticals, Inc.

NasdaqGS OLMA

Olema Pharmaceuticals, Inc. Goodwill for the quarter ending September 30, 2024: USD 0.00

Olema Pharmaceuticals, Inc. Goodwill is USD 0.00 for the quarter ending September 30, 2024, a 0.00% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Olema Pharmaceuticals, Inc. Goodwill for the quarter ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
Olema Pharmaceuticals, Inc. Goodwill for the quarter ending September 30, 2022 was USD 0.00.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NasdaqGS: OLMA

Olema Pharmaceuticals, Inc.

CEO	Dr. Sean P. Bohen M.D., Ph.D.
IPO Date	Nov. 19, 2020
Location	United States
Headquarters	512 2nd Street
Employees	74
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Cosmetics Drugstores & Retail Pharmacies Personal Care Pharmaceuticals

Description

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Key trends

Past 5 years